



## Curriculum Vitae

### Personal information Carmen Ferrajolo

#### Work experience

---

1. Employer: Italian Medicines Agency
  - Start date: 032022
  - End date:
  - Position: Pharmacist \_ Pharmacovigilance Assessor
  - Activities: \_ Assessment of Periodic Safety Update Reports, Post\_Authorisation Safety Studies \_ Safety communication (NUI; NII; DHPC) \_ Referral procedures concerning safety issues \_ Renewal of Marketing Authorisations \_ Implementation and evaluation of COVID\_19 vaccines and therapies
  - Country: Italy
2. Employer: University of Verona \_ Department of Diagnostics and Public Health
  - Start date: 022022
  - End date: 032022
  - Position: Assistant Professor of Pharmacology
  - Activities:
  - Country: Italy
3. Employer: University of Campania "L. Vanvitelli" \_ Department of Experimental Medicine \_ Naples
  - Start date: 012021
  - End date: 012022
  - Position: Scientific researcher \_ PostDOC
  - Activities: Fellowship within research project on "Safety assessment of Immune Checkpoint Inhibitors through the analysis of Spontaneous Reports of adverse drug reactions" funded by Italian Ministry of Education, Universities and Research
  - Country: Italy
4. Employer: University of Campania "L. Vanvitelli" \_ Department of Experimental Medicine \_ Naples
  - Start date: 122015
  - End date: 122020
  - Position: Assistant Professor of Pharmacology
  - Activities: \_ Pharmacovigilance activity (on behalf of Pharmacovigilance and Pharmacoepidemiology Centre of Campania Region) • Data mining and signal detection by using database of adverse drug reactions of Italian National network of Pharmacovigilance (RNF) and European system (EUDRAVIGILANCE); • Case by case assessment; • Application of causality and preventability algorithms \_ Faculty at School of Medicine and School of Pharmacy, University of Campania "L. Vanvitelli", for undergraduate, postgraduate and master courses: • Teaching of Pharmacology, Pharmacovigilance, Pharmacoconomics and Pharmacoepidemiology \_ Scientific research activities by applying pharmacovigilance tools on real world data: design and implementation of post\_marketing observational studies for the assessment of drug/vaccine use and risk\_benefit profile in clinical practice through networks of general practitioners, health databases and databases for spontaneous reporting of adverse drug reactions. Participation and coordination of research activities within national and international projects on active pharmacovigilance and pharmacoepidemiology, funded by the Italian Medicines Agency
  - Country: Italy
5. Employer: Erasmus University Medical Center \_ Department of Medical Informatics \_ Rotterdam
  - Start date: 042014
  - End date: 122015
  - Position: Scientific researcher as post\_doc
  - Activities: Coordination of scientific activity within a multicentre project on pediatrics funded by the European Commission under the 7th Framework Programme "Global Research in pediatrics: the GRIP project". Design and conduction of post\_marketing observational studies on risk/benefit profile of drugs used in children in collaboration with other research centres and international regulatory agencies within this project. Pooled data from different databases from several European countries were used and innovative IT analytic tools were developed and applied for signal detection in pediatrics.
  - Country: Netherlands
6. Employer: University of Campania "L. Vanvitelli" \_ Department of Experimental Medicine \_ Naples
  - Start date: 2007
  - End date: 2010
  - Position: Scientific researcher
  - Activities: Fellowship at dealing with pharmacovigilance procedures
  - Country: Italy

#### Education and training

---

1. Subject: Erasmus Medical Center University \_ Department of Medical Informatics \_ Rotterdam
  - Start date: 2010
  - End date: 112014
  - Qualification: PhD in Pharmacoepidemiology
  - Organisation: Ph.D project: "Drug safety in children: focus on hepatic concerns" published on <https://repub.eur.nl/pub/77131> Skills covered \_ developing and applying new methodological approaches of pooling data in multiple database studies \_ conduction of post\_marketing studies, mainly on pediatric drug safety, within two projects funded by European Commission under the 7th Framework Programme: "Early Detection of Adverse Drug Events by Integrative Mining of

- Clinical Records and Biomedical Knowledge: the EU\_ADR project" and "Global Research in pediatrics: the GRIP project"
- Country: Netherlands
2. Subject: University of Campania "L. Vanvitelli" \_ Department of Experimental Medicine, Pharmacology section \_ Naples
- Start date: 032011
  - End date: 122013
  - Qualification: PhD in Pharmacology Sciences and Clinical and Experimental Medicine
  - Organisation: PhD in Pharmacology with title of Doctor Europeo • Research project: "Identification of potentially drug\_induced acute liver injury in children using a multi\_country healthcare database network" Core curriculum: Pharmacology, Clinical Pharmacology, Pharmacoepidemiology
  - Country: Italy
3. Subject: Netherlands Institute for Health Sciences, NIHES, Erasmus University \_ Rotterdam
- Start date:
  - End date: 2010
  - Qualification: MSc in Clinical Epidemiology
  - Organisation: II level Master of Health Sciences Core curriculum: Study Design, Classical Methods for Data\_analysis, Modern Statistical Methods, Methodologic topics in Epidemiologic Research, Clinical Epidemiology Advanced courses: Cancer Epidemiology, Pharmacoepidemiology and Drug safety, Decision\_making in Medicine, Introduction to Public Health, Clinical Trials, Advanced Analysis of Prognosis Studies Skills courses: working with SPSS
  - Country: Netherlands
4. Subject: University of Campania "L. Vanvitelli" \_ School of Medicine and Surgery \_ Naples
- Start date: 2006
  - End date: 2010
  - Qualification: Specialist in Pharmacology cum laude
  - Organisation: post\_graduate degree with final dissertation "Drug\_induced hepatotoxicity in pediatrics: a case/non case study" Skills covered: data\_mining and data\_analysis on spontaneous reporting system of Adverse Drug Reaction, VIGIBASE \_ Uppsala Monitoring Center of World Health Organisation
  - Country: Italy
5. Subject: University of Naples "Federico II" \_ School of Pharmacy \_ Naples
- Start date: 1998
  - End date: 2004
  - Qualification: PharmD Pharmacy
  - Organisation: Bachelor and Master degrees in Pharmacy. Final dissertation on: "Perchloroethylene: kidney and liver toxicity"
  - Country: Italy

## Additional information

### Publications

Author of 54 publications in international peer\_reviewed journals; 936 citations; h\_index: 20  
<https://www.scopus.com/authid/detail.uri?authorId=37072121200> \_ Roberto G, Girardi A, Barone\_Adesi F, Pecere A, Ientile V, Bartolini C, Da Cas R, Spila\_Alegiani S, Ferrajolo C, et al. Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add\_On to Metformin Monotherapy: A Retrospective Cohort Study. *Front Pharmacol.* 2022 May 30;13:871052. \_ Luxi N, Giovanazzi A, Arcolaci A, Bonadonna P, Crivellaro MA, Cutroneo PM, Ferrajolo, et al. Allergic Reactions to COVID\_19 Vaccines: Risk Factors, Frequency, Mechanisms and Management. *BioDrugs.* 2022 Jul;36(4):443\_458. \_ Sultana J, Crisafulli S, Almas M, Antonazzo IC, Baan E, Bartolini C, Bertuccio MP, Bonifazi F, Capuano A, Didio A, Ehrenstein V, Felisi M, Ferrajolo C, et al; on behalf the Working Group 3 of ENCePP (Inventory of EU data sources and methodological approaches for multisource studies). Overview of the European post\_authorisation study register post\_authorization studies performed in Europe from September 2010 to December 2018. *Pharmacoepidemiol Drug Saf.* 2022 Jun;31(6):689\_705. \_ Gaio M, Ferrajolo C, Zinzi A, Riccardi C, Di Filippo P, Carangelo L, Pieretti G, Rossi F, Nicoletti GF, Capuano A. Association of Direct Oral Anticoagulants (DOACs) and Warfarin With Haemorrhagic Risk by Applying Correspondence Analysis to Data From the Italian Pharmacovigilance Database \_ A Case Study. *Front Pharmacol.* 2021 Dec 7;12:790740. \_ Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP, Ferrajolo C, et al; Ilmiovaccino COVID19 collaborating group. COVID\_19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS\_CoV\_2 Infection: Overview of Current Recommendations and Pre\_ and Post\_Marketing Evidence for Vaccine Efficacy and Safety. *Drug Saf.* 2021 Dec;44(12):1247\_1269. \_ Crisafulli S, Cutroneo PM, Verhamme K, Ferrajolo C, Ficarra V, Sottosanti L, Di Giovanni V, Spina E, Trifirò G. Drug\_induced Urinary Retention: An Analysis of a National Spontaneous Adverse Drug Reaction Reporting Database. *Eur Urol Focus.* 2021 Jul 15:S2405\_4569(21)00180\_2. \_ Rafaniello C, Ferrajolo C, Sullo MG, Gaio M, Zinzi A, Scavone C, Gargano F, Coscioni E, Rossi F, Capuano A. Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System. *Pharmaceuticals (Basel).* 2021 Jun 25;14(7):611. \_ Mascolo A, Scavone C, Ferrajolo C, Rafaniello C, Danesi R, Del Re M, Russo A, Coscioni E, Rossi F, Alfano R, Capuano A. Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance. *Drug Saf.* 2021 Sep;44(9):957\_971. \_ di Mauro G, Zinzi A, Scavone C, Mascolo A, Gaio M, Sportiello L, Ferrajolo C, Rafaniello C, Rossi F, Capuano A. PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database. *Drug Saf.* 2021 Mar;44(3):337\_349. \_ Rafaniello C, Ferrajolo C, Gaio M, Zinzi A, Scavone C, Sullo MG, Rossi F, Berrino L, Capuano A. Tisagenlecleucel in Children and Young Adults: Reverse Translational Research by Using Real\_World Safety Data. *Pharmaceuticals (Basel).* 2020 Sep 21;13(9):258. \_ Sultana J, Mazzaglia G, Luxi N, Cancellieri A, Capuano A, Ferrajolo C, de Waure C, Ferlazzo G, Trifirò G. Potential effects of vaccinations on the prevention of COVID\_19: rationale, clinical evidence, risks, and public health considerations. *Expert Rev Vaccines.* 2020 Oct;19(10):919\_936. \_ Sultana J, Trifirò G, Ientile V, Fontana A, Rossi F, Capuano A, Ferrajolo C. Traceability of Pediatric Antibiotic Purchasing Pathways in Italy: A Nationwide Real\_World Drug Utilization Analysis. *Front Pharmacol.* 2020 Aug 12;11:1232. \_ Mascolo A, Scavone C, Rafaniello C, Ferrajolo C, Racagni G, Berrino L, Paolisso G, Rossi F, Capuano A. Renin\_angiotensin system and Coronavirus disease 2019: A narrative review. Accepted for publication in *Frontiers in Cardiovascular Medicine*, section General Cardiovascular Medicine (July 6, 2020). \_ Ruggiero R, Fraenza F, Scavone C, di Mauro G, Piscitelli R, Mascolo A, Ferrajolo C, Rafaniello C, Sportiello L, Rossi F, Capuano A. *Front Pharmacol.* 2020 Jun 9;11:830. \_ Sultana J, Zaccaria C, de Lisa R, Rossi F, Capuano A, Ferrajolo C. Good Pharmacovigilance Practice in Paediatrics: An Overview of the Updated European Medicines Agency Guidelines. *Paediatr Drugs.* 2019 Oct;21(5):317\_321. \_ Crisafulli S, Sultana J, Ingrassiotta Y, Addis A, Cananzi P, Cavagna L, Conte V, D'Angelo G, Ferrajolo C, Mantovani L, Pastorello M, Scondotto S, Trifirò G. Role of healthcare databases and registries for surveillance of orphan drugs in the real\_world setting: the Italian case study. *Expert Opin Drug Saf.* 2019 Jun;18(6):497\_509. \_ Ferrajolo C, Sultana J, Ientile V, Scavone C, Scondotto G, Tari M, Trifirò G, Rossi F and Capuano A. Gender Differences in Outpatient Pediatric Drug Utilization: a Cohort Study from Southern Italy. *Front. Pharmacol.*, 05 February 2019. \_ Roberto G, Barone\_Adesi F, Giorgianni F, Pizzimenti V, Ferrajolo C, et al. Patterns and trends of utilization of incretin\_based medicines between 2008 and 2014 in three Italian geographic areas. *BMC Endocr Disord.* 2019 Feb 7;19(1):18. \_ Dukanovic J, Osokogu OU, Patel K, Ferrajolo C, Sturkenboom MCMJ; Global Research in Pediatrics project. Comparing drug effectiveness in children: A systematic review. *Pharmacoepidemiol Drug Saf.* 2018 Oct 31. \_ Trifirò G, Gini R, Barone\_Adesi F, Beghi E, Cantarutti A, Capuano A, Carnovale C, Clavenna A, Dellagiovanna M, Ferrajolo C, et al. The Role of European Healthcare Databases for Post\_Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand? *Drug Saf.* 2018 Sep 29. \_ Dodd C, Pacurariu A, Osokogu OU, Weibel D, Ferrajolo C, Vo DH, Becker B, Kors JA, Sturkenboom M. Masking by vaccines in pediatric drug safety signal detection in the Eudravigilance database. *Pharmacoepidemiol Drug Saf.* 2018 Jul 31. \_ Ferrara R, Ientile V, Piccinni C, Pasqua A, Pecchioli S, Fontana A, Alecci U, Scoglio R, Magliozzo F, Torrisi SE, Vancheri C, Vitulo P, Fantaci G, Ferrajolo C, et

al. Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting. *NPJ Prim Care Respir Med*. 2018 Mar 23;28(1):10. \_ Sultana J, Calabrò M, Garcia\_Serna R, Ferrajolo C, Crisafulli C, Mestres J, Trifirò G. Biological substantiation of antipsychotic-associated pneumonia: Systematic literature review and computational analyses. *PLoS One*. 2017 Oct 27;12(10):e0187034. \_ Scavone C, Sportiello L, Sullo MG, Ferrajolo C, et al; BIO\_Cam Group. Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO\_Cam Observational Study. *Front Pharmacol*. 2017 Sep 6;8:607. \_ Ferrajolo C, Scavone C, Donati M, Bortolami O, Stoppa G, Motola D, Vannacci A, Mugelli A, Leone R, Capuano A; DILI\_IT Study Group. Antidepressant-Induced Acute Liver Injury: A Case-Control Study in an Italian Inpatient Population. *Drug Saf*. 2018 Jan;41(1):95-102. \_ Gatto F, Trifirò G, Lapi F, Cocchiara F, Campana C, Dell'Aquila C, Ferrajolo C, Arvigo M, Cricelli C, Giusti M, Ferone D. Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. *Endocrine*. 2018 May 24. doi: 10.1007/s12020-018-1630-4. \_ Cutroneo PM, Giardina C, Tentile V, Potenza S, Sottosanti L, Ferrajolo C, Trombetta CJ, Trifirò G. Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System. *Drug Saf*. 2017 Nov;40(11):1131-1140. \_ Lacava V, Pellicano V, Ferrajolo C, Cernaro V, Visconti L, Conti G, Buemi M, Santoro D. Novel avenues for treating diabetic nephropathy: new investigational drugs. *Expert Opin Investig Drugs*. 2017 Apr;26(4):445-462. \_ Ferrara R, Tentile V, Arcoraci V, Ferrajolo C, Piccinni C, Fontana A, Benvenega S, Trifirò G. Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009-2015. *Endocrine*. 2017 Oct;58(1):143-152. \_ Ferrajolo C, Verhamme KM, Trifirò G, 't Jong GW, Picelli G, Giaquinto C, Mazzaglia G, Stricker BH, Rossi F, Capuano A, Sturkenboom MC. Antibiotic-Induced liver Injury in Paediatric Outpatients: A Case-Control Study in Primary Care Databases. *Drug Saf*. 2017 Apr;40(4):305-315. \_ Rafaniello C, Pozzi M, Pisano S, Ferrajolo C, et al. Second generation antipsychotics in 'real-life' paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. *Expert Opin Drug Saf*. 2016 Dec;15(sup2):1-8. \_ Pozzi M, Pisano S, Bertella S, Capuano A, Rizzo R, Antoniazzi S, Auricchio F, Carnovale C, Cattaneo D, Ferrajolo C, et al. Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients: A 2-Year Naturalistic Comparison. *J Clin Psychiatry*. 2016 Dec;77(12):e1601-e1609. \_ Sultana J, Fontana A, Giorgianni F, Pasqua A, Cricelli C, Spina E, Gambassi G, Ivanovic J, Ferrajolo C, Molokhia M, Ballard C, Sharp S, Sturkenboom M, Trifirò G. The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study. *CNS Drugs*. 2016 Nov;30(11):1097-1109. \_ Osokogu OU, Dukanovic J, Ferrajolo C, Dodd C, Pacurariu AC, Bramer WM, 't Jong G, Weibel D, Sturkenboom MC, Kaguelidou F. Pharmacoepidemiological safety studies in children: a systematic review. *Pharmacoepidemiol Drug Saf*. 2016 Aug;25(8):861-70. \_ Rafaniello C, Ferrajolo C, Sullo MG, Sessa M, Sportiello L, Balzano A, Manguso F, Aiezza ML, Rossi F, Scarpignato C, Capuano A. Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. *Pharmacol Res*. 2016 Feb;104:108-14. \_ Pozzi M, Cattaneo D, Baldelli S, Fucile S, Capuano A, Bravaccio C, Sportiello L, Bertella S, Auricchio F, Bernardini R, Ferrajolo C, et al. Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. *Eur J Clin Pharmacol*. 2016 Mar;72(3):285-93. \_ de Bie S and Ferrajolo C, Straus SM, Verhamme KM, Bonhoeffer J, Wong IC, Sturkenboom MC; GRIP network. Pediatric Drug Safety Surveillance in FDA\_AERS: A Description of Adverse Events from GRIP Project. *PLoS One*. 2015 Jun 19;10(6):e0130399. \_ Rafaniello C, Arcoraci V, Ferrajolo C, Sportiello L, Sullo MG, Giorgianni F, Trifirò G, Tari M, Caputi AP, Rossi F, Esposito K, Giugliano D. Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: A population-based study. *Diabetes Res Clin Pract*. 2015 Apr;108(1):157-63. \_ de Bie S, Coloma PM, Ferrajolo C, Verhamme KM, Trifirò G, Schuemie MJ, Straus SM, Gini R, Herings R, Mazzaglia G, Picelli G, Ghirardi A, Pedersen L, Stricker BH, van der Lei J, Sturkenboom MC; on behalf of the EU\_ADR consortium. The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study. *Br J Clin Pharmacol*. 2015 Aug;80(2):304-14. \_ Osokogu O, Fregonese F, Ferrajolo C, Verhamme K, de Bie S, 't Jong G, Catapano M, Weibel D, Bramer W, Hsia Y, Wong ICK, Gazarian M, Bonhoeffer J, Sturkenboom M. on behalf of the GRIP consortium. Pediatric drug safety signal detection: A new drug-event reference set for performance testing of data-mining methods and systems. *Drug Saf*. 2015 Feb;38(2):207-17. \_ Trifirò G, Parrino F, Sultana J, Giorgianni F, Ferrajolo C, Bianchini E, Medea G, Benvenega S, Cricelli I, Cricelli C, Lapi F. Drug interactions with levothyroxine therapy in patients with hypothyroidism: observational study in general practice. *Clin Drug Investig*. 2015 Mar;35(3):187-95. \_ Italiano D, Capuano A, Alibrandi A, Ferrara R, Cannata A, Trifirò G, Sultana J, Ferrajolo C, et al. Indications of newer and older antiepileptic drug use: findings from a southern Italian general practice setting from 2005-2011. *Br J Clin Pharmacol*. 2014 Dec 31. doi: 10.1111/bcp.12577. \_ Trifirò G, Fatuzzo PM, Tentile V, Pizzimenti V, Ferrajolo C, et al. Expert opinion of nephrologists about the effectiveness of low-protein diet in different stages of chronic kidney disease (CKD). *Int J Food Sci Nutr*. 2014 Dec;65(8):1027-32. \_ Parretta E, Rafaniello C, Magro L, Coggiola Pittoni A, Sportiello L, Ferrajolo C, Mascolo A, Sessa M, Rossi F, Capuano A. Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy. *Expert Opin Drug Saf*. 2014 Sep;13(S1):21-29. \_ Ferrajolo C, Capuano A, Trifirò G, Moretti U, Rossi F, Santuccio C. Pediatric drug safety surveillance in Italian pharmacovigilance network: an overview of adverse drug reactions in the years 2001-2012. *Expert Opin Drug Saf*. 2014 Sep;13(S1):9-20. \_ Ferrajolo C, Arcoraci V, Sullo MG, Rafaniello C, et al. Pattern of statin use in southern Italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment? *PLoS One*. 2014 Jul 29;9(7):e102146. \_ Ferrajolo C, Coloma PM, Verhamme KM, Schuemie MJ, de Bie S, Gini R, Herings R, Mazzaglia G, Picelli G, Giaquinto C, Scotti L, Avillach P, Pedersen L, Rossi F, Capuano A, van der Lei J, Trifirò G, Sturkenboom MC; EU\_ADR consortium. Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network. *Drug Saf*. 2014 Feb;37(2):99-108. \_ Rafaniello C & Lombardo F, Ferrajolo C, Sportiello L, et al. Predictors of Mortality in Atypical Antipsychotics-Treated Community Dwelling Elderly Patients with Behavioural and Psychological Symptoms of Dementia: A Prospective Population-Based Cohort Study from Italy. *Eur J Clin Pharmacol*. 2014 Feb;70(2):187-95. \_ Trifirò G, Italiano D, Alibrandi A, Sini G, Ferrajolo C, Capuano A, Spina E, Rossi A. The Caserta and L'Aquila groups. Effects of L'Aquila earthquake on the prescribing pattern of antidepressant and antipsychotic drugs. *Int J Clin Pharm*. 2013 Dec;35(6):1053-62. \_ Ferrajolo C, Verhamme KM, Trifirò G, 't Jong GW, Giaquinto C, Picelli G, Oteri A, de Bie S, Valkhoff VE, Schuemie MJ, Mazzaglia G, Cricelli C, Rossi F, Capuano A, Sturkenboom MC. Idiopathic Acute Liver Injury in Paediatric Outpatients: Incidence and Signal Detection in Two European Countries. *Drug Saf*. 2013 Oct;36(10):1007-16. \_ Trifirò G, Morabito P, Cavagna L, Ferrajolo C, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. *Ann Rheum Dis*. 2013 May;72(5):694-700. \_ Trifirò G, Tillati S, Spina E, Ferrajolo C, Alacqua M, Aguglia E, Rizzi L, Caputi AP, Cricelli C, Samani F. A nationwide prospective study on prescribing pattern of antidepressant drugs in Italian primary care. *Eur J Clin Pharmacol*. 2013 Feb;69(2):227-36. \_ Coloma PM, Avillach P, Schuemie MJ, Ferrajolo C, Pariente A, Salvo F, Fourrier-Reglat A, Patadia V, Ottosson A, Molokhia M, van der Lei J, Sturkenboom MCJM, and Trifirò G, on behalf of the EU\_ADR consortium. A Reference Standard for Evaluation of Methods for Drug Safety Signal Detection using Electronic Healthcare Records (EHR) Databases. *Drug Saf*. 2013 Jan;36(1):13-23. \_ Ferrajolo C, Capuano A, Verhamme KMC, Schuemie M, Rossi F, Stricker BH, Sturkenboom MCJM. Drug-induced hepatic injury in children: a case/non case study of suspected adverse drug reactions in VigiBase. *Br J Clin. Pharmacol* 2010; 70 (5): 721-8.

## Projects

- Principal Investigator of MUSIC Project (Medicines Use and Safety in Children), funded by the Italian Ministry of Education, Universities and Research under the program "Scientific Independence of young Researchers" (RBSI14X2S5) (2015-2020)
- GRIP, Global Research in Paediatrics, funded by the European Committee under the FP7th (HEALTH\_F5\_2010\_261060). Actively involved in the WP2, coordinated by Erasmus University Medical Center, Rotterdam, the Netherlands (2010-2014);
- DILI\_IT project, funded by Italian Medicines Agency (AIFA) under independent research program (ID Study: FARM8B2TY7), coordinated by University of Verona, Italy (2010-2014);
- EU\_ADR project "Early Detection of Adverse Drug Events by Integrative Mining of Clinical Records and Biomedical Knowledge: the EU\_ADR project" funded by the European Committee under the FP7th and coordinated by Erasmus University Medical Center, Rotterdam, NL (2009-2011);
- SANIARP: regional project, Local Health Unit of Caserta, with the aim to evaluate the appropriateness of medicine prescription from General practitioners (GPs). In details, management and analysis of drug dispensing/prescription records; teaching at seminars to GPs.
- SAFETY OF ANTIPSYCHOTICS IN PAEDIATRICS, University of Campania "Vanvitelli", University of Milan, University of Catania.

## Memberships

\_ Italian Society of Pharmacology (SIF) \_ International Society of Pharmacovigilance (ISOP) \_ ENCePP on behalf of Campania Regional Center of Pharmacovigilance (2012-2017)

## Other Relevant Information

• Award for clinical pharmacology research, included pharmacovigilance, pharmacoepidemiology and pharmacogenetics, assigned by SIF/ASSOGENERICI (2014) • Awards for co\_editor of the online newsletter of SIF (2009\_2016) • Award for Pharmacovigilance by Italian Pharmacology Society (SIF) (2009) • Grant for abroad fellowship sponsored by Italian Pharmacology Society